CIK 0001020214 · Accelerated filer
CERUS CORP
Sign in to watch- Ticker
- CERS
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 680262011
- Phone
- 9252886000
- Business address
- 1220 CONCORD AVENUE, SUITE 600, CONCORD, CA, 94520
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $89,529
- in 1 filing, $90K under 10b5-1 plans
Net −$89,529. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-01 | Green Kevin Dennis Chief Financial Officer | Grant or award · Option (Right to Buy) | +140,000 | 140,000 | ||
| 2022-03-01 | CORASH LAURENCE M Chief Scientific Officer | Grant or award | +45,000 | 2,072,586 | ||
| 2022-03-01 | CORASH LAURENCE M Chief Scientific Officer | Grant or award · Option (Right to Buy) | +90,000 | 90,000 | ||
| 2022-03-01 | Benjamin Richard J Chief Medical Officer | Grant or award | +52,500 | 128,535 | ||
| 2022-03-01 | Benjamin Richard J Chief Medical Officer | Grant or award · Option (Right to Buy) | +105,000 | 105,000 | ||
| 2022-03-01 | Greenman William Mariner President and CEO | Grant or award | +217,500 | 1,811,518 | ||
| 2022-03-01 | Greenman William Mariner President and CEO | Grant or award · Option (Right to Buy) | +435,000 | 435,000 | ||
| 2022-02-25 | Greenman William Mariner President and CEO | Option exercise | +380,000 | $3.75 | $1.4M | 1,902,281 |
| 2022-02-25 | Greenman William Mariner President and CEO | Sale | −215,263 | $5.69 | $1.2M | 1,687,018 |
| 2022-02-25 | Greenman William Mariner President and CEO | Sale | −93,000 | $5.73 | $533K | 1,594,018 |
| 2022-02-25 | Greenman William Mariner President and CEO | Option exercise · Option (Right to Buy) | −380,000 | 0 | ||
| 2022-01-03 | Moore Carol SVP Reg. & Quality | Option exercise | +19,059 | $3.66 | $70K | 200,335 |
| 2022-01-03 | Moore Carol SVP Reg. & Quality | Sale | −19,059 | $7.00 | $133K | 181,276 |
| 2022-01-03 | Moore Carol SVP Reg. & Quality | Option exercise · Option (Right to Buy) | −19,059 | 150,941 | ||
| 2021-12-28 | SCHULZE GAIL Director | Option exercise | +25,000 | $3.19 | $80K | 73,570 |
| 2021-12-28 | SCHULZE GAIL Director | Option exercise · Option (Right to Buy) | −25,000 | 0 | ||
| 2021-12-17 | CORASH LAURENCE M Chief Scientific Officer | Option exercise | +5,000 | $3.75 | $19K | 2,027,586 |
| 2021-12-17 | CORASH LAURENCE M Chief Scientific Officer | Option exercise · Option (Right to Buy) | −5,000 | 0 | ||
| 2021-12-13 | CORASH LAURENCE M Chief Scientific Officer | Option exercise | +40,000 | $3.75 | $150K | 2,022,586 |
| 2021-12-13 | CORASH LAURENCE M Chief Scientific Officer | Option exercise · Option (Right to Buy) | −40,000 | 5,000 |
Page 17 of 27 · 524 trades